

KETAMINEONE CAPITAL LIMITED
(formerly, Myconic Capital Corp.)
810 – 789 West Pender Street
Vancouver, B.C. V6C 1H2

**NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING
OF SHAREHOLDERS**

NOTICE IS HEREBY GIVEN THAT an annual general and special meeting (the "**Meeting**") of the shareholders of KetamineOne Capital Limited (formerly, Myconic Capital Corp.) (the "**Company**") will be held at **810 – 789 West Pender Street, Vancouver, British Columbia V6C 1H2** on **Friday, December 17, 2021 at 11:00 a.m.** (PST) for the following purposes:

1. To receive and consider the financial statements of the Company for the year ended July 31, 2021, and the auditor's report thereon;
2. To set the number of directors to be elected at the Meeting at five (5) and to elect the directors of the Company until the Company's next annual meeting of shareholders;
3. To appoint Macias Gini & O'Connell, LLP, Chartered Professional Accountants as auditors of the Company and to authorize the directors of the Company to fix their remuneration;
4. To consider, and if thought appropriate, to pass, with or without variation, an ordinary resolution ratifying, confirming and approving the restricted share unit plan, as more particularly described in the accompanying Information Circular and attached hereto as Appendix "B";
5. To consider, and if thought appropriate, to pass, with or without variation, an ordinary resolution (the text of which is disclosed in the Information Circular) ratifying, confirming and approving the September Grants (as such term is defined in the Information Circular), as more particularly described in the Information Circular; and
6. To transact such further or other business as may properly come before the Meeting or any adjournment thereof.

The details of the matters proposed to be put before the Meeting are set forth in the accompanying Information Circular, which is supplemental to and expressly made a part of this notice. Shareholders of record as of the close of business on November 12, 2021 (the record date) will be entitled to vote at the Meeting and at any adjournment or adjournments thereof.

DATED at Vancouver, British Columbia, as of the 12th day of November, 2021.

By Order of the Board of Directors
of **KETAMINEONE CAPITAL LIMITED**

"Adam Deffett"

Adam Deffett
Interim CEO

If you are a registered shareholder and are unable to attend the meeting in person, please exercise your right to vote by dating, signing and returning the accompanying form of proxy to Endeavor Trust Corporation., the Company's transfer agent. To be valid, completed proxy forms must be dated, completed, signed and deposited with Endeavor Trust Corporation, (i) by hand delivery or by mail using the enclosed return envelope or one addressed to Endeavor Trust Corporation, Attention: Proxy Department, Suite 702 – 777 Hornby Street, Vancouver, BC V6Z 1S4, or (iii) by facsimile to 1-604-559-8908. If you vote through the internet, you may also appoint another person to be your proxyholder. Please go to <https://www.eproxy.ca/auth/login> and follow the instructions. You will require your control number found on your proxy form. Your proxy or voting instructions must be received in each case no later than 11:00 a.m.

(PST) on Wednesday, December 15, 2021 or, if the meeting is adjourned, 48 hours (excluding Saturdays, Sundays and holidays) before the beginning of any adjourned meeting. If you receive more than one proxy form because you own shares registered in different names or addresses, each proxy form should be completed and returned.

If you are a non-registered shareholder and receive these materials through your broker or through another by intermediary, please complete and return the materials in accordance with the instructions provided to you by your broker or by the other intermediary. Failure to do so may result in your shares not being eligible to be voted by proxy at the Meeting.

In view of the current and rapidly evolving COVID-19 outbreak, the Company asks that, in considering whether to attend the Meeting in person, shareholders follow the instructions of the Public Health Agency of Canada (<https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection.html>). The Company encourages Shareholders not to attend the Meeting in person if experiencing any of the described COVID-19 symptoms of fever, cough or difficulty breathing. The Company may take additional precautionary measures in relation to the Meeting in response to further developments in the COVID-19 outbreak. As always, the Company encourages shareholders to vote prior to the Meeting. Shareholders are encouraged to vote on the matters before the Meeting by proxy and to join the Meeting by teleconference. To access the Meeting by teleconference, dial toll free at 1-800-319-7310, Participation Code: 77783, followed by the # sign.